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Abstract
Background: Systematic reviewers may encounter a multiplicity of outcome data in the reports of randomised
controlled trials included in the review (for example, multiple measurement instruments measuring the same
outcome, multiple time points, and final and change from baseline values). The primary objectives of this study are
to investigate in a cohort of systematic reviews of randomised controlled trials of interventions for rheumatoid
arthritis, osteoarthritis, depressive disorders and anxiety disorders: (i) how often there is multiplicity of outcome data
in trial reports; (ii) the association between selection of trial outcome data included in a meta-analysis and the
magnitude and statistical significance of the trial result, and; (iii) the impact of the selection of outcome data on
meta-analytic results.
Methods/Design: Forty systematic reviews (20 Cochrane, 20 non-Cochrane) of RCTs published from January 2010
to January 2012 and indexed in the Cochrane Database of Systematic Reviews (CDSR) or PubMed will be randomly
sampled. The first meta-analysis of a continuous outcome within each review will be included. From each review
protocol (where available) and published review we will extract information regarding which types of outcome
data were eligible for inclusion in the meta-analysis (for example, measurement instruments, time points, analyses).
From the trial reports we will extract all outcome data that are compatible with the meta-analysis outcome as it is
defined in the review and with the outcome data eligibility criteria and hierarchies in the review protocol. The
association between selection of trial outcome data included in a meta-analysis and the magnitude and statistical
significance of the trial result will be investigated. We will also investigate the impact of the selected trial result on
the magnitude of the resulting meta-analytic effect estimates.
Discussion: The strengths of this empirical study are that our objectives and methods are pre-specified and
transparent. The results may inform methods guidance for systematic review conduct and reporting, particularly for
dealing with multiplicity of randomised controlled trial outcome data.
Keywords: Systematic review, Randomised controlled trials, Reporting, Bias, Research methodology
Background
Systematic reviewers may encounter a multiplicity of
outcome data in the reports of randomised controlled
trials (RCTs) included in their reviews [1-3]. For ex-
ample, within a single RCT report there may be data for
the outcome depression based on multiple measurement
scales (for example, the Hamilton rating scale for de-
pression (HRSD) and the Beck depression inventory
(BDI)), at multiple time points (for example, weeks
three, six, and nine post intervention), and analysed in
multiple ways (for example, as final and change from
baseline values). When there is multiplicity of outcome
data, the selection of data to include in the review
should be based on a clinical or methodological rationale
(or both), and ideally specified a priori. However, in
some cases systematic reviewers may select results based
on the magnitude, direction of effect, or statistical
significance [1,3,4] (henceforth referred to as selective
inclusion). Selective inclusion is problematic as it may* Correspondence: matthew.page@monash.eduSchool of Public Health and Preventive Medicine, Monash University, The
Alfred Centre, 99 Commercial Road, Melbourne, VIC 3004, Australia
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misrepresent the available evidence, leading to selective
inclusion bias [5,6].
An empirical study by Tendal et al. [3] suggested that
multiplicity of outcome data in RCTs is common and
the selected result to include may impact on the meta-
analytic estimate. The authors investigated the extent of
three sources of multiplicity - measurement instruments,
time points, and intervention groups - in 83 RCTs in-
cluded in 19 Cochrane reviews reporting a standardised
mean difference (SMD) meta-analysis. In 18 (of 19)
meta-analyses, at least one type of multiplicity was found
in at least one included RCT. After extracting all RCT
outcome data that were compatible with the inclusion
criteria of the review protocol, Monte Carlo simulations
were used to calculate all possible SMDs for each meta-
analysis. The median difference between the smallest
and largest meta-analytic SMD result was 0.40 (range
0.04 to 0.91), suggesting potential for large and import-
ant variability in meta-analytic results. The authors did
not investigate whether there was an association be-
tween the included result and its characteristics (for ex-
ample, statistical significance, magnitude), or the impact
of other types of multiplicity (for example, multiple ana-
lyses such as intention-to-treat and per-protocol) [3].
Concerns about the potential for selective inclusion
have led to initiatives to minimise its occurrence. The
Cochrane Collaboration Methodological Expectations
for Cochrane Intervention Reviews (MECIR) initiative
and the Institute of Medicine Committee on Standards
for Systematic Reviews of Comparative Effectiveness Re-
search have recently published guidance recommending
that systematic reviewers report detailed protocols that
pre-specify eligible outcome measurement instruments
and time points for inclusion in the review [7,8]. An op-
tional field to provide information on eligible measure-
ment instruments and time points is also available on
the registration form of PROSPERO, an international
online prospective register of systematic reviews launched
in February 2011 [9,10]. Tendal et al. also recommend
that systematic reviewers pre-specify a hierarchy of
measurement instruments and time points when multi-
plicity of outcome data is anticipated (for example,
pre-specifying that HRSD data will be included in a
meta-analysis of depression if both HRSD and BDI data
are reported in studies) [3]. Tendal et al. suggested that
systematic reviewers have not consistently reported
such detailed protocols. For example, while all of the 19
Cochrane protocols reported eligible measurement in-
struments, none reported a hierarchy of measurement
instruments, eight (42%) reported eligible time points
and only one (5%) reported a hierarchy of time points
[3]. These protocols were published prior to 2006 and
no studies have since assessed the frequency of pre-
specification of these and other types of outcome data
eligibility criteria and hierarchies (for example, prefer-
ring adjusted rather than unadjusted effect estimates).
Furthermore, no studies have assessed whether system-
atic review protocols affect selective inclusion of results
in systematic reviews.
Another initiative that may minimise potential selective
inclusion of results is the development of standardised sets
of outcomes (known as core outcome sets) to collect in
clinical trials of a specific condition [11]. Establishing a
core outcome set in RCTs can inform which outcomes
should be included in systematic reviews [12,13]. The earli-
est core outcome sets were developed in the 1990s, for
rheumatoid arthritis (RA) and osteoarthritis (OA) in the
1990s [14-18]. Through the work of the Core Outcome
Measures in Effectiveness Trials (COMET) initiative [19],
core outcome sets are currently being developed for a
range of other conditions. In addition to the core outcomes
in RA and OA studies, recommended measurement in-
struments are also available (for example, the Health As-
sessment Questionnaire to measure function in RA RCTs
[20], and a hierarchy of pain measurement instruments for
use in OA systematic reviews, where a global pain score is
preferred over a pain on walking score if data for both in-
struments are available in an RCT report) [21-23]. In con-
trast, similar guidance does not exist for other conditions
that have neither agreed core outcome sets nor core meas-
urement instruments (for example, depressive and anxiety
disorders) [24-26]. To date there has been no evaluation of
whether core outcome sets affect selective inclusion of re-
sults in systematic reviews.
To our knowledge, no prior work has quantitatively
assessed the evidence for potential bias in meta-analytic
results, which can occur when reviewers selectively in-
clude results from the set available. Quantifying this po-
tential for bias is important as the results of meta-
analyses are used by various stakeholders to inform clin-
ical practice and policy decisions. The aim of this study
is to investigate, in a cohort of systematic reviews, the
potential impact of selective inclusion of RCT results on
meta-analytic effects. The primary objectives of this
study are to investigate: 1) how often there is multiplicity
of outcome data in RCT reports (for example, arising
from multiple measurement scales, time points, and ana-
lyses); 2) the association between the RCT outcome data
included in the meta-analysis and the magnitude and
statistical significance of the RCT result, and 3) the im-
pact of the selection of RCT outcome data on meta-
analytic results.
The secondary objectives are to: 1) quantify how many
systematic review protocols report outcome data eligibil-
ity and hierarchies, and 2) explore how potential select-
ive inclusion of results is modified by (i) the existence of
a systematic review protocol, and (ii) a core outcome set
being available for the clinical condition under review.
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Methods/design
Overview of the study
Forty systematic reviews (20 Cochrane, 20 non-Cochrane)
of RCTs published from January 2010 to January 2012 and
indexed in the Cochrane Database of Systematic Reviews
(CDSR) or PubMed will be randomly sampled. The first
meta-analysis of a continuous outcome within each review
will be included. From each review protocol (where avail-
able) and published review we will extract information re-
garding which types of outcome data were eligible for
inclusion in the meta-analysis (for example, measurement
instruments, time points, analyses). From the RCT reports
we will extract all outcome data that are compatible with
the meta-analysis outcome as it is defined in the review
and with the outcome data eligibility criteria and hierarch-
ies in the review protocol. The association between selec-
tion of RCT outcome data included in a meta-analysis and
the magnitude and statistical significance of the RCT re-
sult will be investigated. We will also investigate the im-
pact of the selected trial result on the magnitude of the
resulting meta-analytic effect estimates.
Eligibility criteria
A systematic review was defined using the definition by
Moher et al.: . . .‘the authors’ stated objective was to
summarize evidence from multiple studies, and the art-
icle described explicit methods, regardless of the details
provided’ [27]. The eligibility criteria for inclusion of
both Cochrane and non-Cochrane systematic reviews in-
clude: 1) the review was published between Issue 1, 2010
to Issue 1, 2012 in the CDSR, or between January 2010
to January 2012 in a non-Cochrane journal; 2) the review
is written in English (as we do not have the resources
available to translate systematic reviews published in other
languages); 3) references of all included RCTs are reported
in the review; 4) the review evaluates the effects of any
intervention for either RA, OA, depressive disorders (in-
cluding major depressive disorder, dysthymic disorder,
bipolar depression, seasonal affective disorder, and post-
partum depression), or anxiety disorders (including gener-
alized anxiety disorder, obsessive-compulsive disorder,
panic disorder, phobic disorders, acute stress disorder, and
post-traumatic stress disorder) [28], and 5) the review in-
cludes at least one continuous outcome meta-analysis of
RCTs (for example, pain, function, number of tender or
swollen joints, depression, anxiety, quality of life), with
reporting of i) either the summary statistics (for example,
mean, SD) or effect estimate and precision of each RCT
included in the meta-analysis, and ii) the meta-analytic ef-
fect estimate and its precision.
We have selected these clinical areas to explore
whether the existence of a core outcome set being avail-
able for the clinical condition of the review (namely, RA
and OA) impacts on selective inclusion of results. We
will focus on continuous outcomes since there is greater
scope for multiplicity of continuous outcomes in these
clinical areas (for example, arising from multiple meas-
urement instruments, final versus change from baseline
values, adjusted versus unadjusted means, sub-scale
scores) compared with dichotomous outcomes. Both
Cochrane and non-Cochrane reviews will be eligible re-
gardless of whether a published protocol for the review
is available. Unpublished protocols will be requested
from authors. Both new and updated reviews will be eli-
gible. For updated reviews, the protocol drafted closest
to the latest update will be included in this study.
The exclusion criteria are: 1) no meta-analyses of con-
tinuous outcomes are reported in the review; 2) results
from non-randomised studies are included in each of
the meta-analyses of continuous outcomes, and 3) non-
standard meta-analytical methods are used (for example,
Bayesian, multiple-treatments, or individual patient data
meta-analyses).
Literature search
We will identify systematic reviews by performing an elec-
tronic search of the CDSR and PubMed. We will use RA
and OA search terms recommended by The Cochrane
Collaboration Musculoskeletal Review Group [29], and de-
pressive and anxiety disorders search terms recommended
by The Cochrane Collaboration Depression, Anxiety and
Neurosis Review Group [30]. For the PubMed search
strategy we will combine the clinical search terms with a
search filter used to identify systematic reviews in a previ-
ous empirical study on the epidemiology and reporting
characteristics of systematic reviews [27]. As the CDSR
only includes records of Cochrane reviews, we will not use
the systematic review search filter in the CDSR search
strategy. We will limit searches to English language publi-
cations and date of publication from 1 January 2010 to 31
January 2012. The search strategies for both databases are
reported in Additional file 1.
Selection of systematic reviews
The citations retrieved from the CDSR and PubMed
databases will be exported to Microsoft Excel and ran-
domly sorted using the random number generator (cita-
tions of Cochrane reviews retrieved in the PubMed
search will be deleted). One investigator (MJP) will read
down the list of randomly sorted citations and screen
the titles and abstracts, marking them as potentially eli-
gible or ineligible. The full text of each potentially eli-
gible systematic review will be retrieved and assessed
against the inclusion criteria. This process will continue
until 10 Cochrane RA or OA reviews, 10 non-Cochrane
RA or OA reviews, 10 Cochrane depressive or anxiety
disorders reviews, and 10 non-Cochrane depressive or
anxiety disorders reviews, are included. Within both
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clinical categories (that is, RA or OA and depressive or
anxiety disorders), we will not constrain the selection by
the particular clinical condition (for example, we will
not require an equal number of reviews of depression
and anxiety). Any difficulties with determining whether
a systematic review meets inclusion criteria will be re-
solved by discussion with a second researcher (JEM).
Selection of continuous outcome for investigation
We will select from each systematic review the first
meta-analysis of a continuous outcome that meets the
inclusion criteria (henceforth referred to as the index
meta-analysis). The index meta-analysis may be selected
from the abstract, summary of findings table, or results
section of the review, depending on where the result is
first reported in the publication. We will not constrain
the selection based on the outcome label of the review
(that is, primary, secondary, or unlabelled), because we
anticipate that in some reviews the primary outcome(s)
may be dichotomous or the primary continuous out-
come may not have been meta-analysed. We will not
constrain the selection based on the domain measured
(for example, pain, or function). Meta-analyses will be
eligible regardless of meta-analytic effect measure (that
is, MD or SMD), meta-analytical model (that is, fixed-
effect or random-effects), and number of RCTs included
(as long as at least two RCTs are included).
Report retrieval
We will retrieve reports of systematic reviews, review
protocols, and RCTs using library services. Reports of
RCTs may comprise journal articles, conference ab-
stracts, unpublished dissertations, or regulatory agency
or pharmaceutical company reports. For RCTs included
in Cochrane reviews with reports written in languages
other than English, we will request a copy of the transla-
tion, if available, from the Cochrane Review Groups, or
will use Google Translate. We will retrieve reports of
RCTs included in the index meta-analysis and those
reported by the systematic reviewers as investigating the
same pairwise comparison but which were excluded
from the meta-analyses (to explore whether any eligible
outcome data may have been missed from these reports
or potentially excluded based on the results). If more
than one reference for an RCT was reported by the sys-
tematic reviewers (for example, both a journal article
and a conference abstract), we will retrieve all references
reported. This will enable investigation of potential se-
lective inclusion resulting from differences in results
reported across different sources [31-33].
Data extraction
One investigator (MJP) will extract data from all reviews
and RCTs into a standardised form created in Microsoft
Excel. This form will be pilot-tested on one review from
each of the four categories (Cochrane RA or OA review,
non-Cochrane RA or OA review, Cochrane depression
or anxiety disorders review, non-Cochrane depression or
anxiety disorders review), and refined accordingly. A
second investigator will independently extract data from
a random sample of 10 reviews and their included RCTs.
If many data extraction discrepancies are identified, we
will consider undertaking double data extraction for the
remaining reviews. Any discrepancies between the data
extracted will be resolved through discussion or adjudi-
cation by a third investigator if necessary. The list of
data we will extract from the systematic review proto-
cols, published systematic reviews, and RCTs is reported
in Additional file 2. A brief summary is provided below.
Data to extract from systematic review protocols
From the systematic review protocol (where available)
we will extract: 1) general characteristics of the review,
including date of publication, and participants, interven-
tions, comparisons, and outcomes of interest to the re-
view; 2) reported outcome data eligibility criteria (for
example, measurement scales, time points, intervention
groups, and/or analyses), and 3) reported outcome data
hierarchies (for example, whether final values were pre-
ferred over change from baseline values if both are
reported in an RCT publication).
Data to extract from published systematic reviews
From the published systematic review, we will extract
the same information as from the protocols. In addition,
we will extract information on any other outcome data
reported in the review that are related measures of the
index meta-analysis outcome under the same compari-
son. For example, if the index meta-analysis outcome is
global pain at 4 to 6 weeks, we will record whether any
outcome data for different pain scales at different time
points were included in the review, either in a subse-
quent meta-analysis or in separate tables; these add-
itional analyses also include sensitivity analyses related
to the index meta-analysis. For the index meta-analysis,
we will extract the following information: 1) the meas-
urement instrument, time point of measurement, and
intervention and comparison group for each RCT; 2)
summary statistics for both groups in each RCT; 3) the
MD or SMD, measures of variability, the statistical sig-
nificance, and direction of the effect estimate for each
RCT and for the meta-analytic effect; 4) heterogeneity
statistics, and 5) which outcome data were obtained
from the trialists because it was not reported in the RCT
publication, involved algebraic manipulation of statistics
(for example, calculating SDs from reported 95% CIs of
the mean), came from a report translated into English,
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or required a method of imputation (such as imputing a
missing SD).
Data to extract from RCT reports
From the RCT reports we will extract all outcome data
that are compatible with the index meta-analysis out-
come as it is defined in the review and with the outcome
data eligibility criteria and hierarchies reported in the re-
view protocol. This could include data from multiple
measurement instruments measuring the same outcome,
multiple time points, multiple intervention or control
groups, final and change from baseline values, intention-
to-treat and per-protocol analyses, adjusted and un-
adjusted effect estimates, and other analyses. For example,
if the index meta-analysis is an MD meta-analysis of de-
pression scores and the systematic reviewers report in the
protocol that only HRSD outcome data will be included in
a meta-analysis of depression, and specify no other out-
come data eligibility criteria, we will extract all data for
the HRSD (for example, all time points, adjusted and un-
adjusted effect estimates), but no data for any other de-
pression measurement instrument reported in the RCTs.
Alternatively, if the index meta-analysis is an SMD meta-
analysis of pain intensity at 12 weeks, and the systematic
reviewers have not pre-specified any outcome data eligibil-
ity criteria or hierarchies, we will extract all pain intensity
data (for example, based on any measurement scale,
intention-to-treat and per-protocol analyses) from each
RCT at 12 weeks only. For systematic reviews without a
protocol, we will request the unpublished protocol from
the systematic reviewers. If one does not exist or is not
provided, we will assume that no outcome data eligibility
criteria or hierarchies were pre-specified, and will extract
all outcome data from the RCTs, as long as they are com-
patible with the index meta-analysis outcome as it is
defined in the review (as per the second example above).
Final and change from baseline values are a special case in
that systematic reviewers performing an SMD meta-
analysis of different measurement instruments should in-
clude only final values or change from baseline values, not
a mixture [34]. For systematic reviews that only include
final values in an SMD meta-analysis, we will not extract
any change from baseline values from the RCTs (and vice
versa for systematic reviews that only include change from
baseline values in an SMD meta-analysis). If systematic re-
viewers include a mixture of final and change from base-
line values in an SMD meta-analysis, we will extract both
types of values from the RCTs.
For each type of RCT outcome data deemed eligible
for inclusion in the meta-analysis, we will extract: 1) the
measurement instrument, time point of measurement,
and intervention and comparison groups; 2) sample sizes,
measures of central tendency, and measures of variability
per group; 3) the effect estimate (MD or SMD) and
measures of variability, the statistical significance, and dir-
ection of the effect estimate; 4) the baseline SD of the out-
come per group, and 5) whether outcome data were fully
reported in the RCT report (where fully reported is de-
fined as reporting sufficient information to include the
data in a meta-analysis [35]). We will use DigitizeIt 1.5.8©
software to extract outcome data presented in figure for-
mat when the data are not available in the text of the re-
port. We will not contact trialists for unpublished data.
Sample size
A study of the characteristics of meta-analyses (with at
least two studies) contained in the January 2008 issue of
the Cochrane Database of Systematic Reviews [36] found
the median number of studies per meta-analysis to be
three. Assuming three RCTs per meta-analysis, a sample
of forty meta-analyses will provide one hundred and
twenty RCTs. This will allow estimation of the proportion
of RCTs with multiplicity of outcome data to within ± 9%
of the true population percentage. This assumes a popula-
tion proportion of 50%, a worst case scenario for the sam-
ple size calculation.
Analysis
Descriptive analyses of general characteristics of systematic
reviews
We will use descriptive statistics to summarise the char-
acteristics of the systematic reviews included in the study.
These characteristics include, for example, the clinical
condition, intervention and comparison type, number of
primary and secondary outcomes (reported in the review
protocol and published review), number of RCTs included
in the review overall, and characteristics of the index
meta-analysis outcome (outcome definition, meta-analytic
effect measure, meta-analytical model, and number of
included RCTs).
Descriptive analyses of reporting of outcome data eligibility
criteria and hierarchies in systematic review protocols and
published reviews
We will calculate the proportion of systematic review
protocols and published reviews reporting at least one
outcome data eligibility criterion and the proportion
reporting at least one outcome data hierarchy. We will
also separately calculate the proportion of protocols and
reviews reporting eligibility criteria and hierarchies in re-
lation to each of the following types of outcome data
multiplicity: 1) multiple measurement instruments; 2)
multiple time points; 3) multiple intervention or control
groups; 4) final and change from baseline values; 5) sets
of participants contributing to the analysis (for example,
intention-to-treat, per-protocol, as-treated); 6) unadjusted
and adjusted effect estimates; 7) period results in cross-
over RCTs, and 8) other. Further, we will calculate the
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proportion of systematic reviews with at least one discrep-
ancy in outcome data eligibility criteria and hierarchies
between the protocol and published review (where a dis-
crepancy is defined as an addition, removal, or modifica-
tion of an eligibility criterion or hierarchy).
Quantifying outcome data multiplicity in RCT reports
We will calculate the proportion of RCTs with at least
one type of outcome data multiplicity that is compatible
with the index meta-analysis outcome as it is defined in
the review and with the outcome data eligibility criteria
and hierarchies reported in the review protocol. We will
also calculate the proportion of RCTs with the following
types of outcome data multiplicity: 1) multiple measure-
ment instruments; 2) multiple time points; 3) multiple
intervention or control groups; 4) final and change from
baseline values; 5) sets of participants contributing to the
analysis (for example, intention-to-treat, per-protocol, as-
treated); 6) unadjusted and adjusted effect estimates; 7)
period results in crossover RCTs, and 8) other. In addition,
for each RCT we will quantify the number of effect esti-
mates that were eligible for inclusion in the index meta-
analysis, and will quantify the median (interquartile range)
of eligible effect estimates per RCT. We will also quantify
the number of eligible effect estimates that were not in-
cluded in the index meta-analysis but were included in
other meta-analyses or elsewhere in the review (for ex-
ample, tables).
Testing the association between selection of outcome data
and the magnitude and statistical significance of the effect
estimate
When multiple effect estimates are available for inclu-
sion in a meta-analysis, without pre-specified selection
rules, several different methods may be acceptable (in
terms of not introducing bias) for selecting an effect esti-
mate from the set available. These mechanisms may in-
clude: 1) selecting data for the most commonly reported
instrument, time point, or analysis across RCTs; 2) ran-
dom selection of an effect estimate; 3) selection of the
median effect estimate, and 4) selection of the outcome
data based on clinical criteria. The commonality of these
selection methods is that the selection of the effect esti-
mate is not based on choosing systematically higher or
lower effect estimates. If across the RCTs, selection
methods 1) to 4) are employed, we would expect that
the distribution of selected effect estimates would be
consistent with what we would observe under purely
random selection, although this does not necessarily
mean that the process used to select the effect estimates
was indeed random selection.
We have developed an index, which we call the Poten-
tial Bias Index (PBI), to assess whether the estimates
selected for inclusion in the index meta-analysis are
systematically higher or lower than what would be
expected by purely random selection. This index is based
on the ordered effect estimates for each trial and the po-
sitioning (that is, rank) of the effect estimate selected
within that order. A rank of 1 is assigned to the smallest
effect estimate and a rank equal to the number of effect
estimates is assigned to the largest effect estimate. Since
the number of effect estimates varies across trials we
rescale the ranks of the effect estimates to reflect their
relative positioning (in ranking units) between the
smallest and largest effect estimates. This is obtained by
subtracting one from the rank of the selected effect esti-
mate and dividing by the number of effect estimates
minus one. The smallest effect estimate in a trial then
has a location of zero and the largest effect estimate has
a location of 1. So for a trial with three effect estimates
and the rank of the chosen effect estimate of 2, its loca-
tion is (2–1)/(3–1) = 0.5 - halfway between the lowest
and highest rank. The Potential Bias Index (PBI) is de-
fined as the weighted average of the locations of the se-
lected estimates for each trial, with the weights being
the number of effect estimates in each trial. With this
weighting, greater priority is given to the locations of ef-
fect estimates the larger the number of effect estimates
there were to choose from. The expression for PBI is:
PBI ¼
Xk
i¼1
ni Xi  1ð Þ
ni  1 =
Xk
i¼1ni
where there are k trials, ni is the number of effect esti-
mates in trial i, and Xi is the rank of the selected effect
estimate in trial i. Derivation of this index and a worked
example is provided in Additional files 3 and 4. Only tri-
als with more than one effect estimate are included in
the PBI since a trial with one effect estimate provides no
information about relative location. When the largest ef-
fect estimate in each of the trials is selected for inclu-
sion, the PBI will have the value 1, and conversely PBI =
0 when the smallest effect estimate is always selected.
Under a process consistent with random selection, the
PBI is expected to take the value of 0.5, so, on average
the chosen effect estimates are at the middle location.
Similarly, a PBI of 0.75 would indicate that on average
the effect estimates chosen were 75% of the distance
between the smallest and largest ranks, or equivalently
halfway between the middle and highest rank. We have
constructed a simple statistical test based on the PBI to
test whether the observed selection of effect estimates is
consistent with randomness of selection (see Additional
file 3). Confidence intervals for the PBI can be constructed
using bootstrap methods by resampling individual trials
[37]. We will also apply the PBI to assess possible selec-
tion mechanisms in which the smaller P-values of the ef-
fect estimates are chosen for inclusion.
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Impact of selection of outcome data on meta-analytic
results
The PBI described above will also be used to compare
the index meta-analytic effect estimates with all possible
meta-analytic effects. For each meta-analysis, all possible
meta-analytic effects will be calculated from all combi-
nations of available RCT effect estimates. The meta-
analysis model used to combine the estimates (either
fixed or random effects) will be the model that was used
in the systematic review. However, sensitivity analyses
will be undertaken to examine whether the type of
meta-analysis model affects the PBI.
We will also investigate the impact of the selected
RCT effects on the magnitude of the resulting meta-
analytic effect estimates. For each meta-analysis, the
difference between the index meta-analytic effect esti-
mate and the median of all possible meta-analytic effect
estimates will be calculated. These differences will be
standardised (by dividing by the pooled baseline SD of
the outcome) and meta-analysed using a random-effects
model across reviews. The meta-analytic weights will be
based on the standardised standard error of the median
meta-analytic estimates, and between RCT variability es-
timated using DerSimonian and Laird’s method of mo-
ments estimator [38]. Note that this approach ignores
the correlation between the meta-analytic effects within
meta-analysis, arising from correlated RCT effects.
Subgroup analyses
We will examine whether the existence of 1) a system-
atic review protocol and 2) a core outcome set being
available for the clinical condition of the review affects
a) the specificity of outcome data eligibility criteria and
hierarchies reported in systematic review protocols and
published reviews; b) the proportion of RCTs with multi-
plicity and the proportion of systematic reviews with at
least one RCT with multiplicity; c) the PBI of the RCT
effect estimates selected for inclusion in the index meta-
analysis, and d) the PBI of the resulting index meta-
analytic effect estimates.
Sensitivity analyses
For systematic reviews without protocols, it is not known
whether the outcome eligibility criteria reported in the
methods section of the review were specified prior, or sub-
sequent to undertaking the review. Therefore, for our pri-
mary analyses, we have chosen to include the set of RCT
effect estimates that are compatible with the assumption
of no pre-specified outcome data eligibility criteria. How-
ever, through sensitivity analyses, we plan to investigate if
the PBIs (calculated at both the RCT and meta-analysis
level) are modified when the set of RCT effect estimates
are restricted to those that are compatible with the
outcome data eligibility criteria and hierarchies specified
in the methods section of the review.
Discussion
To our knowledge, this is the first empirical study
designed to investigate the association between selection
of RCT outcome data included in a meta-analysis and
the magnitude and statistical significance of the RCT
result. In publishing this protocol we are following the
lead of others who have encouraged the pre-specification
and transparent reporting of the objectives and design of
methodological studies [39-43].
There are several strengths of our study. We will use
systematic review methods to identify eligible reviews,
including use of explicit inclusion criteria, sensitive search
strategies, duplicate selection of reviews, and standardised
and pilot-tested data extraction forms. We will perform
double data-extraction on a random sample of reviews
and their included RCTs, and will consider performing
this on the complete sample if the data extraction discrep-
ancy rate is high. In addition to exploring whether there is
evidence of selective inclusion of RCT results in system-
atic reviews, we will examine what the potential impact of
this is on meta-analytic estimates.
There are also several limitations to our study. We are fo-
cusing only on meta-analyses of continuous outcomes, and
so will not investigate potential selective inclusion arising
from types of multiplicity unique to dichotomous outcomes
(for example, binary events defined in multiple ways, or
continuous measurement instruments dichotomised using
different cut-points). Our study is also limited to systematic
reviews of RA, OA, depressive disorders and anxiety
disorders. Some of the continuous outcomes likely to be in-
cluded in our study (for example, pain, function, and quality
of life) exist in systematic reviews of other conditions (such
as low-back pain), but our findings may have limited gener-
alisability to other clinical areas. However, our focus on
continuous outcomes and these clinical areas enables us to
examine the impact of core outcome sets on selective inclu-
sion of results. Finally, our study will only investigate the
existence of potential bias in meta-analytic effect estimates
that can result from systematic reviewers’ selective inclusion
of results reported by trialists. It is possible that the effect
estimate(s) available in an RCT publication may have been
selectively reported by the trialists (for example, data col-
lected using other measurement scales may have been
omitted based on the results). Therefore, both selective
reporting by trialists and selective inclusion by systematic
reviewers may in combination bias the results of a meta-
analysis [6]; however, our analysis will only examine the
latter.
Meta-analysis results are of interest to various stake-
holders and are used to inform clinical practice and pol-
icy decisions. If the results of meta-analyses are biased
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by selective inclusion of results, additional methods
guidance for systematic review conduct and reporting
will be necessary. Systematic review organisations have
only recently recommended that systematic reviewers
pre-specify eligible measurement instruments and time
points in their protocols [7,8]. This advice may need to
be extended to encompass other common types of out-
come data multiplicity.
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protocols, published systematic reviews, and randomised controlled
trial (RCT) reports.
Additional file 3: Mathematical details of the construction of the
Potential Bias Index (PBI) and associated statistical test.
Additional file 4: Worked example of the Potential Bias Index.
Abbreviations
BDI: Beck depression inventory; CDSR: Cochrane Database of Systematic
reviews; HRSD: Hamilton rating scale for depression; IOM: Institute of
Medicine; MD: Mean difference; MECIR: Methodological Expectations for
Cochrane Intervention Reviews; OA: Osteoarthritis; PBI: Potential Bias Index;
RA: Rheumatoid arthritis; RCT: Randomised controlled trial;
SMD: Standardised mean difference.
Competing interests
MJP has roles within The Cochrane Collaboration including systematic
review trainer for the Australasian Cochrane Centre, member of the Bias
Methods Group, Statistical Methods Group, and Trainer’s Network, and
author of Cochrane systematic reviews. JEM has roles within The Cochrane
Collaboration including Co-convenor of the Statistical Methods Group,
member of the Methods Board and the Bias Methods Group, Statistical
Editor of the Consumers and Communication Review Group, and author of
Cochrane systematic reviews. SEG has roles within The Cochrane
Collaboration including Co-Director of the Australasian Cochrane Centre, past
editor of the Cochrane Handbook of Systematic Reviews of Interventions,
and author of Cochrane systematic reviews managed by the Cochrane
Collaboration Musculoskeletal Review Group (though not rheumatoid
arthritis or osteoarthritis reviews). ABF has no competing interests to declare.
Authors’ contributions
MJP and JEM conceived the study design. MJP wrote the first draft, with
contributions from JEM. SEG and ABF provided input on the study design.
ABF developed the Potential Bias Index, test statistics, and simulations. All
authors contributed to revisions of the manuscript and take public
responsibility for its content.
Acknowledgements
This work forms part of MJP’s PhD, which is supported by an Australian
Postgraduate Award administered through Monash University, Australia.
Received: 9 January 2013 Accepted: 25 March 2013
Published: 10 April 2013
References
1. Bender R, Bunce C, Clarke M, Gates S, Lange S, Pace NL, Thorlund K:
Attention should be given to multiplicity issues in systematic reviews.
J Clinical Epidemiol 2008, 61:857–865.
2. Tendal B, Higgins JPT, Jüni P, Hróbjartsson A, Trelle S, Nüesch E, Wandel S,
Jørgensen AW, Gesser K, Ilsøe-Kristensen S, Gøtzsche PC: Disagreements in
meta-analyses using outcomes measured on continuous or rating scales:
observer agreement study. BMJ 2009, 339:b3128.
3. Tendal B, Nüesch E, Higgins JPT, Jüni P, Gøtzsche PC: Multiplicity of data in
trial reports and the reliability of meta-analyses: empirical study.
BMJ 2011, 343:d4829.
4. Bjordal JM, Bogen B, Lopes-Martins BRA, Klovning A: Can Cochrane reviews
in controversial areas be biased? A sensitivity analysis based on the
protocol of a systematic Cochrane review on low-level laser therapy in
osteoarthritis. Photomed Laser Surg 2005, 23:453–458.
5. Page MJ, McKenzie JE, Dwan K, Kirkham J, Green S, Forbes A: Bias due to
selective inclusion and reporting of outcomes and analyses in
systematic reviews of randomised trials of healthcare interventions
(Protocol). Cochrane Database Syst Rev 2012, 5:MR000035.
6. Page MJ, McKenzie JE, Forbes A: Many scenarios exist for selective
inclusion and reporting of results in randomized trials and systematic
reviews. J Clin Epidemiol 2013, 66:524–537.
7. Chandler J, Churchill R, Higgins J, Lasserson T, Tovey D: Methodological
standards for the conduct of new Cochrane Intervention Reviews. 2011.
Version 2.1, 8 December 2011. [http://www.editorial-unit.cochrane.org/
mecir].
8. IOM (Institute of Medicine): Finding what works in health care: standards for
systematic reviews. Washington, DC: The National Academies Press; 2011.
9. Booth A, Clarke M, Ghersi D, Moher D, Petticrew M, Stewart L: Establishing
a minimum dataset for prospective registration of systematic reviews: an
international consultation. PLoS One 2011, 6:e27319.
10. Booth A, Clarke M, Dooley G, Ghersi D, Moher D, Petticrew M, Stewart L:
The nuts and bolts of PROSPERO: an international prospective register of
systematic reviews. Systematic Reviews 2012, 1:2.
11. Williamson P, Altman D, Blazeby J, Clarke M, Gargon E: Driving up the
quality and relevance of research through the use of agreed core
outcomes. J Health Serv Res Policy 2012, 17:1–2.
12. Clarke M: Standardising outcomes for clinical trials and systematic
reviews. Trials 2007, 8:39.
13. Williamson PR, Clarke M: The COMET (Core Outcome Measures in
Effectiveness Trials) Initiative: its role in improving Cochrane Reviews
[editorial]. Cochrane Database Syst Rev 2012, 5, ED000041.
14. Tugwell P, Boers M: OMERACT conference on outcome measures in
rheumatoid arthritis clinical trials: introduction. J Rheumatol 1993,
20:528–530.
15. Boers M, Tugwell P, Felson DT, van Riel PL, Kirwan JR, Edmonds JP, Smolen
JS, Khaltaev N, Muirden KD: World Health Organization and International
League of Associations for Rheumatology core endpoints for symptom
modifying antirheumatic drugs in rheumatoid arthritis clinical trials.
J Rheumatol 1994, S41:86–89.
16. Tugwell P, Boers M, Brooks P, Simon L, Strand V, Idzerda L: OMERACT: An
international initiative to improve outcome measurement in
rheumatology. Trials 2007, 8:38.
17. Cranney ATP, Shea B, Wells G: Implications of OMERACT outcomes in
arthritis and osteoporosis for Cochrane metaanalysis. J Rheumatol 1997,
24:1206–1207.
18. Altman R, Brandt K, Hochberg M, Moskowitz R, Bellamy N, Bloch DA,
Buckwalter J, Dougados M, Ehrlich G, Lequesne M, Lohmander S, Murphy
WA Jr, Rosario-Jansen T, Schwartz B, Trippel S: Design and conduct of
clinical trials in patients with osteoarthritis: Recommendations from a
task force of the Osteoarthritis Research Society: Results from a
workshop. Osteoarthr Cartil 1996, 4:217–243.
19. COMET Initiative. http://www.comet-initiative.org/.
20. Fries JF, Spitz P, Kraines RG, Holman HR: Measurement of patient outcome
in arthritis. Arthritis Rheum 1980, 23:137–145.
21. McAlindon TE, LaValley MP, Gulin JP, Felson DT: Glucosamine and
chondroitin for treatment of osteoarthritis. JAMA 2000, 283:1469–1475.
22. Jüni P, Reichenbach S, Dieppe P: Osteoarthritis: rational approach to
treating the individual. Best Pract Res Clin Rheumatol 2006, 20:721–740.
23. Reichenbach S, Sterchi R, Scherer M, Trelle S, Bürgi E, Bürgi U, Dieppe PA,
Jüni P: Meta-analysis: chondroitin for osteoarthritis of the knee or hip.
Ann Intern Med 2007, 146:580–590.
24. Tyler KM, Normand S-LT, Horton NJ: The use and abuse of multiple
outcomes in randomized controlled depression trials. Contemp Clin Trials
2011, 32:299–304.
25. Demyttenaere K, De Fruyt J: Getting what you ask for: on the selectivity
of depression rating scales. Psychother Psychosom 2003, 72:61–70.
26. Balon R: Rating scales for anxiety/anxiety disorders. Curr Psychiatry Rep
2007, 9:271–277.
Page et al. Systematic Reviews 2013, 2:21 Page 8 of 9
http://www.systematicreviewsjournal.com/content/2/1/21
27. Moher D, Tetzlaff J, Tricco AC, Sampson M, Altman DG: Epidemiology and
reporting characteristics of systematic reviews. PLoS Med 2007, 4:e78.
28. American Psychiatric Association: Diagnostic and Statistical Manual of Mental
Disorders (DSM-IV-TR). Fourth Edition, Text Revision. Washington, DC:
American Psychiatric Association; 2000.
29. Cochrane Musculoskeletal Group. http://onlinelibrary.wiley.com/o/cochrane/
clabout/articles/MUSKEL/frame.html.
30. Cochrane Depression Anxiety and Neurosis Group. http://onlinelibrary.wiley.
com/o/cochrane/clabout/articles/DEPRESSN/frame.html.
31. Bohlius J, Weingart O, Trelle S, Engert A: Disentangling the data: variations in
data submissions from different players and their potential impact on a
systematic review [abstract]. Melbourne, Australia: XIII Cochrane Colloquium.
2005:60. 2005 Oct 22–26 [http://onlinelibrary.wiley.com/o/cochrane/clcmr/
articles/CMR-7839/frame.html].
32. Chokkalingam A, Scherer R, Dickersin K: Agreement of data in abstracts
compared to full publications. Control Clin Trials 1998, 3(Suppl 1):61S–62S.
33. Dundar Y, Dodd S, Dickson R, Walley T, Haycox A, Williamson PR:
Comparison of conference abstracts and presentations with full-text
articles in the health technology assessments of rapidly evolving
technologies. Health Technol Assess 2006, 10:1–145.
34. Deeks JJ, Higgins JPT, Altman DG: Chapter 9: Analysing data and
undertaking meta-analyses. In Cochrane Handbook of Systematic Reviews of
Interventions. Version 5.1.0 [updated March 2011]. Edited by Higgins JPT,
Green S. The Cochrane Collaboration; 2011. www.cochrane-handbook.org.
35. Chan AW, Hrobjartsson A, Haahr MT, Gotzsche PC, Altman DG: Empirical
evidence for selective reporting of outcomes in randomized trials:
comparison of protocols to published articles. JAMA 2004, 291:2457–2465.
36. Davey J, Turner R, Clarke M, Higgins J: Characteristics of meta-analyses
and their component studies in the Cochrane Database of Systematic
Reviews: a cross-sectional, descriptive analysis. BMC Med Res Methodol
2011, 11:160.
37. Efron B, Tibshirani RJ: An introduction to the bootstrap. New York, NY:
Chapman & Hall; 1993.
38. DerSimonian R, Laird N: Meta-analysis in clinical trials. Control Clin Trials
1986, 7:177–188.
39. Akl E, Briel M, You J, Lamontagne F, Gangji A, Cukierman-Yaffe T, Alshurafa
M, Sun X, Nerenberg K, Johnston B, et al: LOST to follow-up Information in
Trials (LOST-IT): a protocol on the potential impact. Trials 2009, 10:40.
40. Briel M, Lane M, Montori V, Bassler D, Glasziou P, Malaga G, Akl E, Ferreira-
Gonzalez I, Alonso-Coello P, Urrutia G, Kunz R, Culebro C, da Silva S, Flynn D,
Elamin M, Strahm B, Murad MH, Djulbegovic B, Adhikari N, Mills E, Gwadry-
Sridhar F, Kirpalani H, Soares H, Elnour N, You J, Karanicolas P, Bucher H,
Lampropulos J, Nordmann A, Burns K, et al: Stopping randomized trials
early for benefit: a protocol of the Study Of Trial Policy Of Interim
Truncation-2 (STOPIT-2). Trials 2009, 10(1):49.
41. Sun X, Briel M, Busse J, Akl E, You J, Mejza F, Bala M, Diaz-Granados N,
Bassler D, Mertz D, Srinathan S, Vandvik P, Malaga G, Alshurafa M, Dahm P,
Alonso-Coello P, Heels-Ansdell D, Bhatnagar N, Johnston B, Wang L, Walter
S, Altman D, Guyatt G: Subgroup Analysis of Trials Is Rarely Easy (SATIRE):
a study protocol for a systematic review to characterize the analysis,
reporting, and claim of subgroup effects in randomized trials. Trials 2009,
10:101.
42. Kasenda B, von Elm E, You J, Blumle A, Tomonaga Y, Saccilotto R, Amstutz
A, Bengough T, Meerpohl J, Stegert M, Tikkinen K, Neumann I, Carrasco-
Labra A, Faulhaber M, Mulla S, Mertz D, Akl E, Bassler B, Busse J, Ferreira-
Gonzalez I, Lamontagne F, Nordmann A, Rosenthal R, Schandelmaier S, Sun
X, Vandvik P, Johnston B, Walter M, Burnand B, Schwenkglenks M, et al:
Learning from Failure - Rationale and Design for a Study about
Discontinuation of Randomized Trials (DISCO study). BMC Med Res
Methodol 2012, 12:131.
43. Feys F, Bekkering G, Singh K, Devroey D: Do randomized clinical trials with
inadequate blinding report enhanced placebo effects for intervention
groups and nocebo effects for placebo groups? A protocol for a meta-
epidemiological study of PDE-5 inhibitors. Syst Rev 2012, 1:54.
doi:10.1186/2046-4053-2-21
Cite this article as: Page et al.: An empirical investigation of the
potential impact of selective inclusion of results in systematic reviews
of interventions: study protocol. Systematic Reviews 2013 2:21.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Page et al. Systematic Reviews 2013, 2:21 Page 9 of 9
http://www.systematicreviewsjournal.com/content/2/1/21
